• Consensus Rating: Hold
  • Consensus Price Target: $161.12
  • Forecasted Upside: 1.10%
  • Number of Analysts: 16
  • Breakdown:
  • 0 Sell Ratings
  • 9 Hold Ratings
  • 7 Buy Ratings
  • 0 Strong Buy Ratings
$159.37
▲ +1.45 (0.92%)

This chart shows the closing price for ABBV by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New AbbVie Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ABBV and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ABBV

Analyst Price Target is $161.12
▲ +1.10% Upside Potential
This price target is based on 16 analysts offering 12 month price targets for AbbVie in the last 3 months. The average price target is $161.12, with a high forecast of $200.00 and a low forecast of $140.00. The average price target represents a 1.10% upside from the last price of $159.37.

This chart shows the closing price for ABBV for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 16 polled investment analysts is to hold stock in AbbVie. This rating has held steady since October 2022, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 10 buy ratings
  • 4 hold ratings
  • 0 sell ratings
10/8/2021
  • 0 strong buy ratings
  • 9 buy ratings
  • 5 hold ratings
  • 0 sell ratings
1/6/2022
  • 0 strong buy ratings
  • 9 buy ratings
  • 7 hold ratings
  • 0 sell ratings
4/6/2022
  • 0 strong buy ratings
  • 9 buy ratings
  • 7 hold ratings
  • 0 sell ratings
7/5/2022
  • 0 strong buy ratings
  • 8 buy ratings
  • 8 hold ratings
  • 0 sell ratings
10/3/2022
  • 0 strong buy ratings
  • 6 buy ratings
  • 8 hold ratings
  • 0 sell ratings
1/1/2023
  • 0 strong buy ratings
  • 7 buy ratings
  • 9 hold ratings
  • 0 sell ratings
3/2/2023
  • 0 strong buy ratings
  • 7 buy ratings
  • 9 hold ratings
  • 0 sell ratings
4/1/2023

Latest Recommendations

  • 0 strong buy ratings
  • 7 buy ratings
  • 9 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/28/2023GuggenheimInitiated CoverageBuy$172.00Low
2/22/2023Wolfe ResearchDowngradeOutperform ➝ Peer PerformLow
2/10/2023Atlantic SecuritiesLower TargetNeutral$157.00 ➝ $154.00Low
2/10/2023Morgan StanleyLower TargetOverweight$182.00 ➝ $178.00Low
2/10/2023Piper Jaffray CompaniesBoost TargetOverweight$157.00 ➝ $163.00Low
2/10/2023SVB LeerinkUpgradeUnderperform ➝ Market Perform$135.00 ➝ $153.00Low
2/10/2023SVB SecuritiesUpgradeUnderperform ➝ Market Perform$135.00 ➝ $153.00Low
2/9/2023Piper SandlerBoost TargetOverweight$157.00 ➝ $163.00Low
2/6/2023BMO Capital MarketsLower TargetOutperform$169.00 ➝ $167.00Low
1/17/2023Piper SandlerBoost TargetOverweight$155.00 ➝ $157.00Low
1/5/2023Truist FinancialBoost Target$160.00 ➝ $180.00Low
12/6/2022Morgan StanleyBoost TargetOverweight$178.00 ➝ $182.00Low
11/17/2022Credit Suisse GroupInitiated CoverageOutperform$170.00Low
11/8/2022Societe GeneraleDowngradeBuy ➝ Hold$155.00 ➝ $140.00Low
10/31/2022Atlantic SecuritiesLower TargetNeutral$162.00 ➝ $157.00Low
10/31/2022Morgan StanleyLower TargetOverweight$185.00 ➝ $178.00Low
10/31/2022BarclaysLower TargetEqual Weight$160.00 ➝ $155.00Low
10/31/2022BMO Capital MarketsLower TargetOutperform$170.00 ➝ $169.00Low
10/11/2022Morgan StanleyLower TargetOverweight$188.00 ➝ $185.00Low
9/30/2022SVB LeerinkLower TargetUnderperform$140.00 ➝ $135.00Low
8/24/2022ArgusLower TargetBuy$165.00 ➝ $155.00Low
8/9/2022BarclaysLower Target$160.00N/A
8/1/2022Morgan StanleyLower TargetOverweight$191.00 ➝ $188.00Low
8/1/2022UBS GroupLower TargetNeutral$154.00 ➝ $146.00Low
8/1/2022Atlantic SecuritiesLower TargetOverweight ➝ Neutral$178.00 ➝ $162.00Low
7/29/2022Piper SandlerLower Target$160.00 ➝ $155.00Low
7/27/2022UBS GroupBoost TargetOutperform$154.00Low
7/8/2022Morgan StanleyBoost TargetOverweight$188.00 ➝ $191.00N/A
5/23/2022SVB LeerinkInitiated CoverageUnderperform$140.00High
5/6/2022Daiwa Capital MarketsDowngradeOutperform ➝ Neutral$150.00Low
5/2/2022Wells Fargo & CompanyBoost Target$165.00 ➝ $200.00Medium
4/25/2022BMO Capital MarketsBoost TargetOutperform$161.00 ➝ $174.00Medium
4/12/2022The Goldman Sachs GroupBoost TargetNeutral$122.00 ➝ $140.00High
4/12/2022BarclaysBoost TargetEqual Weight$150.00 ➝ $174.00High
4/6/2022Morgan StanleyBoost TargetOverweight$142.00 ➝ $192.00Medium
3/1/2022CitigroupBoost Target$155.00 ➝ $170.00Low
2/28/2022UBS GroupDowngradeBuy ➝ Neutral$129.00 ➝ $147.00Low
2/4/2022MizuhoBoost TargetBuy$154.00 ➝ $166.00Low
2/3/2022JPMorgan Chase & Co.Boost Target$165.00 ➝ $180.00Low
2/3/2022Bank of AmericaBoost TargetNeutral$135.00 ➝ $138.00Medium
2/3/2022The Goldman Sachs GroupBoost TargetNeutral$117.00 ➝ $122.00Medium
2/3/2022BMO Capital MarketsBoost TargetOutperform$153.00 ➝ $154.00Medium
2/3/2022BarclaysBoost TargetEqual Weight ➝ Equal Weight$133.00 ➝ $150.00High
1/27/2022CitigroupBoost Target$125.00 ➝ $155.00Medium
1/24/2022Morgan StanleyBoost TargetOverweight$124.00 ➝ $142.00Medium
1/20/2022BarclaysBoost TargetEqual Weight$118.00 ➝ $133.00High
1/18/2022CowenBoost Target$130.00 ➝ $150.00High
1/13/2022Redburn PartnersInitiated CoverageBuyHigh
1/12/2022BMO Capital MarketsBoost TargetOutperform$134.00 ➝ $153.00Low
1/5/2022MizuhoBoost TargetBuy$132.00 ➝ $154.00Medium
1/3/2022Piper SandlerBoost Target$129.00 ➝ $160.00Low
12/17/2021The Goldman Sachs GroupInitiated CoverageNeutral$113.00High
12/8/2021Wells Fargo & CompanyInitiated CoverageOverweight$165.00High
12/7/2021BMO Capital MarketsReiterated RatingBuy$134.00Low
12/7/2021SVB LeerinkReiterated RatingBuyLow
11/24/2021Truist FinancialBoost TargetBuy$118.00 ➝ $135.00Low
11/23/2021Societe GeneraleUpgradeHold ➝ BuyHigh
11/1/2021BarclaysBoost TargetEqual Weight$112.00 ➝ $118.00Low
11/1/2021SVB LeerinkLower TargetOutperform$142.00 ➝ $135.00Low
11/1/2021Morgan StanleyBoost TargetOverweight$116.00 ➝ $124.00Low
10/29/2021Piper SandlerBoost TargetOverweight$124.00 ➝ $129.00Low
9/2/2021SVB LeerinkLower TargetOutperform$148.00 ➝ $142.00Medium
8/23/2021CowenBoost TargetOutperform$120.00 ➝ $130.00Low
8/20/2021Morgan StanleyReiterated RatingBuy$116.00Low
8/20/2021SVB LeerinkBoost TargetOutperform$145.00 ➝ $148.00Low
8/5/2021ArgusBoost TargetBuy ➝ Buy$130.00 ➝ $140.00Low
8/2/2021SVB LeerinkBoost TargetOutperform$144.00 ➝ $145.00Medium
8/2/2021MizuhoBoost TargetBuy$128.00 ➝ $131.00Medium
8/2/2021BarclaysBoost TargetEqual Weight$105.00 ➝ $112.00Medium
7/27/2021Truist FinancialInitiated CoverageBuy$117.00Low
7/2/2021Daiwa Capital MarketsInitiated CoverageOutperformLow
5/3/2021BMO Capital MarketsBoost TargetOutperform$127.00 ➝ $129.00High
5/3/2021MizuhoBoost TargetBuy$126.00 ➝ $128.00High
4/30/2021Piper SandlerBoost TargetOverweight$120.00 ➝ $124.00Low
4/7/2021Royal Bank of CanadaInitiated Coverage$135.00Low
3/30/2021SVB LeerinkBoost TargetOutperform$140.00 ➝ $144.00Low
2/4/2021SVB LeerinkBoost TargetIn-Line ➝ Outperform$128.00 ➝ $140.00Low
2/4/2021Royal Bank of CanadaBoost TargetOutperform$129.00 ➝ $135.00Low
2/4/2021MizuhoBoost TargetBuy$117.00 ➝ $126.00Low
1/28/2021Morgan StanleyLower TargetOverweight$120.00 ➝ $116.00Medium
12/16/2020SVB LeerinkBoost TargetOutperform$119.00 ➝ $128.00Medium
12/15/2020MizuhoBoost Target$111.00 ➝ $117.00Medium
11/30/2020Morgan StanleyBoost TargetPositive ➝ Overweight$108.00 ➝ $120.00Low
11/18/2020BMO Capital MarketsInitiated CoverageOutperform$123.00 ➝ $123.00Medium
11/10/2020Sanford C. BernsteinInitiated CoverageOutperform$120.00High
11/2/2020SVB LeerinkLower TargetOutperform$122.00 ➝ $119.00High
10/23/2020Truist FinancialInitiated CoverageBuy$110.00Low
10/20/2020The Goldman Sachs GroupDowngradeNeutral ➝ SellHigh
10/16/2020JPMorgan Chase & Co.Boost TargetOverweight$115.00 ➝ $120.00Low
9/29/2020Berenberg BankInitiated CoverageHold$98.00Low
9/27/2020MizuhoReiterated RatingBuy$111.00Low
9/2/2020CitigroupBoost TargetBuy$98.00 ➝ $105.00Medium
8/20/2020Morgan StanleyBoost TargetOverweight$95.00 ➝ $108.00Medium
8/3/2020MizuhoBoost TargetBuy$110.00 ➝ $111.00Low
8/3/2020Royal Bank of CanadaBoost TargetOutperform$125.00 ➝ $127.00Low
6/29/2020MizuhoBoost TargetTop Pick ➝ Buy$101.00 ➝ $110.00Low
6/25/2020Royal Bank of CanadaBoost TargetOutperform$102.00 ➝ $125.00Medium
6/23/2020Atlantic SecuritiesUpgradeNeutral ➝ Overweight$115.00Medium
6/18/2020Royal Bank of CanadaReiterated RatingBuy$102.00Low
6/17/2020UBS GroupBoost Target$96.00 ➝ $109.00Low
6/10/2020Evercore ISIInitiated CoverageBuy$111.00High
6/10/2020Piper SandlerBoost Target$97.00 ➝ $110.00High
6/9/2020Wolfe ResearchUpgradePeer Perform ➝ OutperformLow
6/2/2020ArgusUpgradeHold ➝ Buy$91.40 ➝ $115.00Low
5/28/2020Royal Bank of CanadaReiterated RatingBuy$102.00Low
5/18/2020Bank of AmericaInitiated CoverageNeutral$95.00Low
5/12/2020JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$105.00Medium
5/11/2020Morgan StanleyReiterated RatingOverweight$95.00High
5/11/2020SVB LeerinkBoost TargetOutperform$107.00 ➝ $122.00High
5/4/2020SVB LeerinkBoost TargetOutperform$103.00 ➝ $107.00Low
5/1/2020MizuhoReiterated RatingBuy$100.00Medium
4/20/2020Royal Bank of CanadaUpgradeSector Perform ➝ Outperform$79.00 ➝ $93.00Low
4/13/2020UBS GroupLower TargetBuy$106.00 ➝ $96.00Low
4/12/2020Royal Bank of CanadaReiterated RatingHold$79.00Low
3/23/2020Societe GeneraleDowngradeBuy ➝ HoldHigh
2/27/2020BarclaysInitiated CoverageEqual Weight$97.00 ➝ $97.00High
2/18/2020CowenBoost TargetOutperform$98.00 ➝ $105.00Low
2/10/2020MizuhoBoost Target$96.00 ➝ $104.00High
2/7/2020Piper SandlerBoost TargetOverweight$95.00 ➝ $97.00Low
2/5/2020MizuhoInitiated CoverageBuy$96.00 ➝ $96.00Low
1/23/2020Royal Bank of CanadaReiterated RatingHold$86.00High
1/6/2020Royal Bank of CanadaInitiated CoverageSector Perform$86.00Low
1/3/2020Bank of AmericaDowngradeBuy ➝ NeutralLow
12/26/2019CowenBoost TargetOutperform$90.00 ➝ $98.00Low
11/20/2019CitigroupBoost TargetBuy$90.00 ➝ $98.00Medium
11/19/2019UBS GroupBoost TargetBuy$79.00 ➝ $96.00High
11/1/2019Piper Jaffray CompaniesBoost Target$81.00 ➝ $90.00High
9/26/2019CitigroupUpgradeNeutral ➝ Buy$87.00 ➝ $90.00Medium
9/24/2019CowenSet TargetBuy$90.00Low
9/12/2019UBS GroupUpgradeNeutral ➝ Buy$85.00 ➝ $79.00Low
9/4/2019Piper Jaffray CompaniesBoost TargetOverweight$80.00 ➝ $81.00Medium
8/20/2019Piper Jaffray CompaniesUpgradeNeutral ➝ Overweight$80.00High
7/26/2019Piper Jaffray CompaniesSet TargetHold$80.00N/A
7/2/2019SVB LeerinkUpgradeBuyLow
6/27/2019Wolfe ResearchUpgradeUnderperform ➝ Peer PerformMedium
6/26/2019CitigroupReiterated RatingHoldMedium
6/26/2019SVB LeerinkUpgradeMarket Perform ➝ Outperform$88.00High
5/28/2019The Goldman Sachs GroupInitiated CoverageNeutral ➝ Neutral$84.00High
4/28/2019BMO Capital MarketsUpgradeUnderperform ➝ Market Perform$71.00 ➝ $79.00Low
4/26/2019Credit Suisse GroupSet TargetSell$78.00Low
3/25/2019ArgusDowngradeBuy ➝ HoldLow
2/14/2019BarclaysReiterated RatingHold$86.00Low
1/25/2019Credit Suisse GroupSet TargetHold$79.00High
1/23/2019UBS GroupReiterated RatingNeutral ➝ Neutral$97.00 ➝ $91.00Low
1/17/2019Credit Suisse GroupUpgradeHold$79.00Medium
1/3/2019Bank of AmericaDowngradeBuy ➝ NeutralMedium
12/26/2018Standpoint ResearchInitiated CoverageBuy ➝ BuyHigh
12/20/2018Morgan StanleySet TargetHold$88.00High
11/6/2018ArgusLower TargetBuy ➝ Buy$130.00 ➝ $115.00Low
11/5/2018BMO Capital MarketsLower TargetUnderperform ➝ Underperform$78.00 ➝ $71.00Low
11/4/2018BarclaysReiterated RatingHold$90.00High
11/2/2018Credit Suisse GroupSet TargetHold$85.00High
10/23/2018Wolfe ResearchInitiated CoverageUnderperformLow
10/22/2018SunTrust BanksLower TargetBuy ➝ Buy$157.00 ➝ $135.00High
10/20/2018Credit Suisse GroupSet TargetSell$85.00High
10/14/2018Credit Suisse GroupSet TargetHold$85.00Medium
10/4/2018Bank of AmericaLower TargetBuy ➝ Buy$107.00 ➝ $106.00Medium
8/22/2018Bank of AmericaBoost TargetBuy ➝ Buy$105.00 ➝ $107.00Low
8/22/2018BMO Capital MarketsReiterated RatingSell$78.00Low
7/30/2018Bank of AmericaLower TargetBuy ➝ Buy$112.00 ➝ $105.00Medium
7/27/2018Piper Jaffray CompaniesReiterated RatingHold$100.00Low
7/27/2018CowenSet TargetBuy$110.00Low
7/27/2018BMO Capital MarketsReiterated RatingSell$78.00Low
7/15/2018Jefferies Financial GroupSet TargetBuy$100.00Low
7/13/2018Credit Suisse GroupUpgradeHold$89.00Low
7/12/2018Berenberg BankInitiated CoverageHold$105.00Low
6/11/2018ArgusLower TargetBuy ➝ Buy$145.00 ➝ $130.00Low
6/6/2018Credit Suisse GroupSet TargetSell$89.00Low
6/1/2018Piper Jaffray CompaniesDowngradeOverweight ➝ Neutral$125.86 ➝ $66.62Low
5/30/2018Deutsche Bank AktiengesellschaftDowngradeNeutral ➝ Underperform$125.86 ➝ $65.61Medium
5/30/2018Deutsche Bank AktiengesellschaftDowngradeNeutral ➝ Underperform$125.86 ➝ $65.61Low
5/29/2018Credit Suisse GroupDowngradeNeutral ➝ Sell$104.00 ➝ $89.00Medium
5/24/2018The Goldman Sachs GroupDowngradeConviction-Buy ➝ BuyHigh
5/23/2018BMO Capital MarketsLower TargetUnderperform ➝ Underperform$81.00 ➝ $78.00Low
5/1/2018BMO Capital MarketsReiterated RatingSell$81.00Low
4/30/2018Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$131.00 ➝ $110.00High
4/27/2018Credit Suisse GroupLower TargetNeutral ➝ Neutral$109.00 ➝ $104.00Medium
4/22/2018Credit Suisse GroupSet TargetHold$109.00Low
4/13/2018Jefferies Financial GroupSet TargetBuy$122.00Low
4/10/2018Credit Suisse GroupSet TargetHold$109.00Low
4/5/2018BarclaysLower TargetEqual Weight ➝ Equal Weight$120.00 ➝ $102.00Low
4/5/2018BMO Capital MarketsReiterated RatingSell$80.00Low
(Data available from 4/1/2018 forward)

News Sentiment Rating

0.91 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 18 very positive mentions
  • 42 positive mentions
  • 2 negative mentions
  • 3 very negative mentions
9/3/2022
  • 22 very positive mentions
  • 50 positive mentions
  • 7 negative mentions
  • 5 very negative mentions
10/3/2022
  • 27 very positive mentions
  • 42 positive mentions
  • 8 negative mentions
  • 3 very negative mentions
11/2/2022
  • 27 very positive mentions
  • 31 positive mentions
  • 3 negative mentions
  • 5 very negative mentions
12/2/2022
  • 24 very positive mentions
  • 17 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
1/1/2023
  • 29 very positive mentions
  • 12 positive mentions
  • 6 negative mentions
  • 2 very negative mentions
1/31/2023
  • 37 very positive mentions
  • 47 positive mentions
  • 4 negative mentions
  • 2 very negative mentions
3/2/2023
  • 32 very positive mentions
  • 18 positive mentions
  • 5 negative mentions
  • 1 very negative mentions
4/1/2023

Current Sentiment

  • 32 very positive mentions
  • 18 positive mentions
  • 5 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

AbbVie logo
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.
Read More

Today's Range

Now: $159.37
Low: $157.73
High: $159.57

50 Day Range

MA: $151.79
Low: $144.61
High: $159.37

52 Week Range

Now: $159.37
Low: $134.09
High: $175.91

Volume

4,957,340 shs

Average Volume

6,995,534 shs

Market Capitalization

$281.15 billion

P/E Ratio

24.11

Dividend Yield

3.75%

Beta

0.62

Frequently Asked Questions

What sell-side analysts currently cover shares of AbbVie?

The following sell-side analysts have issued research reports on AbbVie in the last year: Argus, Atlantic Securities, Barclays PLC, BMO Capital Markets, Credit Suisse Group AG, Daiwa Capital Markets, Guggenheim, Morgan Stanley, Piper Jaffray Companies, Piper Sandler, Societe Generale, StockNews.com, SVB Leerink LLC, SVB Securities, The Goldman Sachs Group, Inc., Truist Financial Co., UBS Group AG, Wells Fargo & Company, and Wolfe Research.
View the latest analyst ratings for ABBV.

What is the current price target for AbbVie?

17 Wall Street analysts have set twelve-month price targets for AbbVie in the last year. Their average twelve-month price target is $161.12, suggesting a possible upside of 1.1%. Wells Fargo & Company has the highest price target set, predicting ABBV will reach $200.00 in the next twelve months. The Goldman Sachs Group, Inc. has the lowest price target set, forecasting a price of $140.00 for AbbVie in the next year.
View the latest price targets for ABBV.

What is the current consensus analyst rating for AbbVie?

AbbVie currently has 9 hold ratings and 7 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in ABBV, but not buy more shares or sell existing shares.
View the latest ratings for ABBV.

What other companies compete with AbbVie?

How do I contact AbbVie's investor relations team?

AbbVie's physical mailing address is 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL, 60064. The company's listed phone number is (847) 932-7900. The official website for AbbVie is www.abbvie.com. Learn More about contacing AbbVie investor relations.